News Column

Synageva Biopharma Corp. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 24, 2014)

July 9, 2014



By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Synageva Biopharma Corp. (Form 4) was posted on June 24, 2014.

The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).

There was one document filed with this form. The SEC file number is 0001144204-14-039293.

The contact information for this company is 33 HAYDEN AVE., LEXINGTON MA 02421, (781) 357-9900.

Our editors provided additional information about Form 4: Every director, officer or owner of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act must file with the Commission a statement of ownership regarding such security. The initial filing is on Form 3 and changes are reported on Form 4. The Annual Statement of beneficial ownership of securities is on Form 5. The forms contain information on the reporting person's relationship to the company and on purchases and sales of such equity securities.

A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.

For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1087939/0001144204-14-039293-index.html.

Keywords for this news article include: Pharmaceutical Companies, Drugs, Therapy, SEC Filing, Biopharmaceuticals, Biological Products, Synageva Biopharma Corp., (No Diagnostic Substances).

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters